UPM Biomedicals Conference 2023 - Dr. Thomas Lundbäck, AstraZeneca

The 9th Annual UPM Biomedicals Conference took place on the 31st of October 2023 as a hybrid event from Helsinki, Finland.
Here research and industry experts share their insights and experiences on many different aspects of 3D cell culture, from quality assessment and optimization of organoid models to animal-free solutions and economic benefits of 3D models. The conference is open to all and offers both educational and networking opportunities.
Read more at www.upmbiomedicals.com or contact us at [e-mail]
Thomas Lundbäck has been with Discovery Sciences and AstraZeneca for seven years and he transitioned into his current role as Senior Director in 2022. He is responsible for the Mechanistic Biology team in Sweden with the remit to provide world-class SAR profiling and bespoke mechanism of action studies across multiple drug modalities including small molecules, peptides, PROTACs, antisense oligonucleotides and siRNA. His organization primarily serves the Cardiovascular, Renal, and Metabolism and the Respiratory and Immunology therapy area organisations, but also Neuroscience and the Alexion AstraZeneca rare disease portfolio.
Thomas has more than 25 years of experience in life science research, including several transitions between academia and industry. He received his PhD in biophysics at the Karolinska Institutet, and following postdoctoral studies at University College London and Yale University, he joined Pharmacia & Upjohn in 1999, where he spent 10 years. Prior to joining AstraZeneca, Thomas worked with the biophysics portfolio of products at GE Healthcare before he went back to the Karolinska Institutet. There he worked at Chemical Biology Consortium Sweden (CBCS), a national infrastructure for chemical biology research. It is in this setting that he encountered the cellular thermal shift assay (CETSA) and played a key role in the addition of HTS-compatible readouts to the technology.
Thomas brings a rich external network, which he leverages as an experienced organizer of scientific meetings, with the ELRIG Advances in Cell-Based Screening meeting in 2022 and the ELRIG Therapeutic OLIGO meeting in 2023 as highlights. Additional external roles include his service as chairman of the steering groups for CBCS and the Chemical Biology and Genome Engineering platform at SciLifeLab, a member of the ELRIG Science Strategy Committee, and the Industry Liaison Office for the EU-OPENSCREEN DRIVE project. Thomas is also an Associate Editor of the ASSAY and Drug Development Technologies journal.
► UPM
We deliver renewable and responsible solutions and innovate for a future beyond fossils across six business areas: UPM Biorefining, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers and UPM Plywood. As the industry leader in responsibility, we are committed to the UN Business Ambition for 1.5°C and the science-based targets to mitigate climate change. We employ 18,000 people worldwide and our annual sales are approximately EUR 8.6 billion. Our shares are listed on Nasdaq Helsinki Ltd. UPM Biofore - Beyond fossils. upm.com
► SOCIAL MEDIA
• Facebook ➭ / upmglobal
• Twitter ➭ / upmglobal
• LinkedIn ➭ / 28653740